Life Sciences

  • April 14, 2026

    Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told

    Hedge fund Armistice Capital and two of its executives exploited the COVID-19 pandemic to issue press releases that falsely inflated their controlling share in pharmaceutical company Vaxart, then dumped the shares for $250 million before the bottom fell out, investors told a California federal jury at the start of trial Tuesday.

  • April 14, 2026

    4th Circ. Revives Pharma Bid To Block Maryland's 340B Law

    A split Fourth Circuit panel on Tuesday tossed a Maryland district court's order denying a preliminary injunction to pharmaceutical manufacturers that have challenged a state law addressing drug delivery in the federal 340B discount program, pointing to its recent ruling that West Virginia's similar statute is likely preempted.

  • April 14, 2026

    States Denied Time For Talks To Settle Drug Price-Fixing Suit

    A Connecticut federal judge Tuesday denied a request by dozens of U.S. states to freeze their antitrust case against generic-drug manufacturers, a pause the states argued would allow the parties to focus on settlement talks rather than pending discovery and motion deadlines.

  • April 14, 2026

    Justices Told That Eli Lilly's FCA Qui Tam Challenge Too Late

    A whistleblower who secured a $183 million trial win against Eli Lilly urged the U.S. Supreme Court on Tuesday to reject its constitutional challenge over his ability to sue for the federal government, arguing the drugmaker's arguments came too late.

  • April 14, 2026

    Trade Group Latest To Sue Wash. Over 340B Drug Pricing Law

    Pharmaceutical Research and Manufacturers of America claims a new Washington state law attempts to illegally reshape the federal 340B Drug Pricing Program and singles out participating drugmakers with burdensome regulations, according to a fresh federal lawsuit that follows similar constitutional challenges mounted by Novartis and AbbVie.

  • April 14, 2026

    Vertex Sues Former Exec To Block Move To Rival

    Vertex Pharmaceuticals asked a Massachusetts state court judge to bar a former executive from taking a virtually identical role at competitor Vera Therapeutics, citing a noncompete agreement he allegedly signed.

  • April 14, 2026

    FDA Offers Guidance On Safety Testing For Gene-Editing Tech

    The U.S. Food and Drug Administration on Tuesday issued draft guidance recommending steps drug companies should take to evaluate the safety of gene-editing technology as they seek federal approval for cutting-edge treatments aimed at genetic diseases.

  • April 14, 2026

    3rd Circ. Upholds J&J Injunction Bid Loss In Biosimilar Fight

    The Third Circuit on Tuesday ruled that a Johnson & Johnson subsidiary couldn't justify its bid for an order blocking Samsung Bioepis from paving the way for a Cigna unit to launch a generic version of an anti-inflammatory treatment.

  • April 14, 2026

    Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal

    Venture-backed pre-clinical biotechnology firm CrossBridge Bio Inc., advised by Cooley LLP, on Tuesday announced that it has agreed to be bought by pharmaceutical giant Eli Lilly & Co. in a deal worth up to $300 million.

  • April 14, 2026

    Mich. AG Says PBMs Can't Duck Drug-Pricing Suit

    Two pharmacy benefit managers can't dodge an antitrust lawsuit accusing them of price-fixing reimbursement rates because Michigan has properly claimed an antitrust violation, state Attorney General Dana Nessel told a federal court, asking it to toss aside the PBMs' dismissal bid. 

  • April 14, 2026

    4th Circ. Won't Rehear Allergan Overcharge Suit

    The Fourth Circuit on Tuesday denied a rehearing petition lodged after a panel revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid.

  • April 14, 2026

    Buyers Seek Final Approval Of $4.85M Bayer Benzene Deal

    A class of consumers is asking a New Jersey federal court to give final approval of a $4.85 million settlement to resolve claims that Bayer US LLC's antifungal products were contaminated with benzene.

  • April 14, 2026

    Avanos Medical Going Private In $1.3B Deal Led By 3 Firms

    American Industrial Partners has agreed to acquire Avanos Medical Inc. in an all-cash transaction valued at nearly $1.3 billion, a take-private deal steered by three law firms, Avanos announced Tuesday. 

  • April 14, 2026

    State AGs, Albertsons Chain Reach $773M Opioid Deal

    Albertsons Cos. Inc. and the attorneys general of California, Colorado, Illinois and Oregon on Tuesday said that the pharmacy and grocery chain had agreed to a $773 million settlement in principle to end claims brought by states, local governments and Native American tribes over its role in the opioid crisis.

  • April 14, 2026

    Omnicare OK'd For Ch. 11 Auction With $250M Base Bid

    Pharmacy services provider Omnicare's choice of a $250 million stalking horse bid for its assets was approved Tuesday by a Texas bankruptcy judge, setting up a possible auction in May.

  • April 13, 2026

    Oracle Wins TRO Against Ex-Worker Threatening Secrets Sale

    A North Carolina federal judge Monday issued a temporary restraining order barring a recently laid-off Oracle sales employee from disclosing trade secrets that the software firm alleges he has threatened to sell to the "highest bidder" unless he receives an "unreasonable" fee.

  • April 13, 2026

    Citron's 'Shadowy Gang' Sued Over Short Selling Campaign

    Shareholders of PolarityTE have alleged in a new suit that "members of a shadowy gang of short sellers" conspired to short the biotechnology company's stock through targeted negative media attacks with Citron Research to enrich themselves at the expense of the shareholders, and that they ultimately caused the company's bankruptcy.

  • April 13, 2026

    Ill. Judge Wants More Proof To Recalculate Kickback Damages

    An Illinois federal judge tasked with recalculating damages from a home health company's referral kickback scheme said Monday that she needs more complete and reliable evidence to help determine the appropriate amount, but allowed the government to continue offsetting Medicare payments as part of its judgment collection bid.

  • April 13, 2026

    FTC Ends Teen Height Growth Supplement Claims

    A supplement maker and its owners agreed to pay $750,000 to end claims they misled customers into thinking their products could make their children taller, the Federal Trade Commission announced on Monday.

  • April 13, 2026

    Del. Judge Ends 80K Pre-2026 Zantac Cases

    A Delaware state court on Monday dismissed more than 80,000 suits filed before December alleging that Boehringer Ingelheim's discontinued heartburn medication Zantac caused cancer, following a Delaware Supreme Court ruling on admissibility of the plaintiffs' experts.

  • April 13, 2026

    Obesity Drugmaker Leads 2 Biotech Startups Eyeing IPOs

    Two biotechnology startup companies on Monday filed plans for their public debuts, with obesity-focused Kailera Therapeutics planning to raise an estimated $500 million in its initial public offering and protein biomarker detection platform Alamar Biosciences planning to raise around $150 million.

  • April 13, 2026

    Mylan Can't Revive Copaxone Antitrust Claims Against Teva

    A New Jersey federal judge sided Monday with a special master's recommendations to nix some of the parallel claims from Mylan and retailers like Walgreens accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment.

  • April 13, 2026

    Hikma Tells Justices Cox Ruling Boosts 'Skinny Label' Case

    Hikma Pharmaceuticals USA Inc. told the U.S. Supreme Court on Monday that the justices' recent decision clearing an internet company in a copyright case bolsters the drugmaker's challenge to a patent suit over its generic version of an Amarin Pharma Inc. heart drug.

  • April 13, 2026

    VC Apple Tree Seeks $7M As Judge Mulls Ch. 11 Funding Fight

    Biotech investor Apple Tree Life Sciences Inc. asked a Delaware bankruptcy judge to let it use $7 million from a larger funding motion she has yet to rule on, saying it needs the money for operating expenses and drug development costs.

  • April 13, 2026

    AI Cardiac Imaging Co. Hits Ex-Consultant With IP Suit

    Artificial intelligence-powered cardiac imaging company Heartflow Inc. filed patent infringement and trade secret misappropriation claims on Monday against a competitor founded by a former consultant who, the company says, lifted technological trade secrets while he was under contract.

Expert Analysis

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

  • Software Patents May Face New Eligibility Scrutiny

    Author Photo

    November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.

  • Opinion

    A Uniform Federal Rule Would Curb Gen AI Missteps In Court

    Author Photo

    To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.

  • Riding The Changing Winds For AI Innovations At The USPTO

    Author Photo

    As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.

  • Series

    The Law Firm Merger Diaries: Integrating Practice Groups

    Author Photo

    Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.